Compare UHS & ELAN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | UHS | ELAN |
|---|---|---|
| Founded | 1978 | 1954 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Hospital/Nursing Management | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.4B | 12.7B |
| IPO Year | 1994 | 2018 |
| Metric | UHS | ELAN |
|---|---|---|
| Price | $182.96 | $23.78 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 11 | 10 |
| Target Price | ★ $233.00 | $27.89 |
| AVG Volume (30 Days) | 531.4K | ★ 4.3M |
| Earning Date | 04-27-2026 | 05-06-2026 |
| Dividend Yield | ★ 0.45% | N/A |
| EPS Growth | ★ 37.34 | N/A |
| EPS | ★ 23.10 | N/A |
| Revenue | ★ $17,364,829,000.00 | $4,715,000,000.00 |
| Revenue This Year | $7.70 | $8.21 |
| Revenue Next Year | $4.96 | $5.31 |
| P/E Ratio | $7.75 | ★ N/A |
| Revenue Growth | ★ 9.71 | 6.22 |
| 52 Week Low | $152.33 | $8.33 |
| 52 Week High | $246.33 | $27.72 |
| Indicator | UHS | ELAN |
|---|---|---|
| Relative Strength Index (RSI) | 44.06 | 49.28 |
| Support Level | $181.18 | $22.17 |
| Resistance Level | $187.82 | $23.70 |
| Average True Range (ATR) | 4.94 | 0.91 |
| MACD | 0.90 | 0.03 |
| Stochastic Oscillator | 56.39 | 66.18 |
Universal Health Services primarily offers healthcare services through its behavioral health centers, acute care hospitals, and related outpatient facilities. As of late 2025, the company operated 346 inpatient behavioral health centers, 29 acute care hospitals, and many supportive outpatient facilities. Its operations are concentrated in the US, particularly in Nevada (21% of 2025 operating profits), Texas (19%), and California (13%), although it does have some exposure to the UK behavioral health market (6% of 2025 sales) too. While its acute care services account for over 55% of revenue, the behavioral health centers sport higher margins and account for over 55% of pretax profits.
Elanco Animal Health is an animal health company that is engaged in developing, manufacturing, and marketing pharma products for companion and food animals. It spun off from Eli Lilly in 2018 and acquired Janssen Animal Health in 2011, Novartis Animal Health in 2014, Boehringer Ingelheim Vetmedica in 2017, and Bayer Animal Health in 2020. The company's operations are conducted globally, and it sells its products in over 90 countries. It offers a range of food animal products used in cattle, sheep, goats, and swine production.